ProShare Advisors’s CorMedix CRMD Stock Holding History

ProShare Advisors’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$96.8K	Sell	12,332 -1,956	-14%	-$15.5K	﹤0.01%	1776
2026 Q1	$97K	Sell	14,288 -2,776	-16%	-$20.5K	﹤0.01%	1713
2025 Q4	$198K	Buy	17,064 +2,360	+16%	+$26.1K	﹤0.01%	1724
2025 Q3	$171K	Sell	14,704 -1,008	-6%	-$12.2K	﹤0.01%	1732
2025 Q2	$194K	Sell	15,712 -147	-0.9%	-$1.62K	﹤0.01%	1734
2025 Q1	$97.7K	Sell	15,859 -4,088	-20%	-$42.3K	﹤0.01%	1840
2024 Q4	$162K	Buy	19,947 +9,568	+92%	+$95.6K	﹤0.01%	1950
2024 Q3	$83.9K	Buy	+10,379	New	+$56.2K	﹤0.01%	1909

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

ProShare Advisors's CRMD Position: Q2 2026 in Review

ProShare Advisors reduced its CorMedix (CRMD) stake by 14% in Q2 2026, selling an estimated $15.5K and leaving 12,332 shares worth $96.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1776.

ProShare Advisors first reported a position in CRMD in Q3 2024 and has held it in 8 quarters since. The position peaked at $198K in Q4 2025. 193 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

ProShare Advisors held 12,332 shares of CorMedix worth $96.8K as of Q2 2026.
ProShare Advisors sold 1,956 CorMedix shares in Q2 2026, an estimated $15.5K.
CorMedix made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1776 holding.
ProShare Advisors first reported a position in CorMedix in Q3 2024 and has held it in 8 quarters since.
ProShare Advisors's CorMedix position peaked at $198K in Q4 2025.
193 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.